about
Accuracy of recall of information about a cancer-predisposing BRCA1/2 gene mutation among patients and relatives.Comparing family members' motivations and attitudes towards genetic testing for hereditary breast and ovarian cancer: a qualitative analysis.Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trialCost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testingThe Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services.Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer riskGenetic Testing for Rare Cancer: The Wider Issues.Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations.Communicating BRCA1/2 genetic test results within the family: a qualitative analysis.Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK.Doing the right thing for one's children: deciding whether to take the genetic test for Huntington's disease as a moral dilemma.The development of a methodology for examining the process of family communication of genetic test results.Identifying individuals who might benefit from genetic services and information.Genetics in palliative oncology: a missing agenda? A review of the literature and future directions.Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.Providing a community-based cancer risk assessment service for a socially and ethnically diverse population.Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population.The PiGeOn project: protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer.Patient perspectives on molecular tumor profiling: "Why wouldn't you?"Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancerNo news is (not necessarily) good news: impact of preliminary results for BRCA1 mutation searchesNovel one-stop multidisciplinary follow-up clinic for BRCA1/2 carriers: patient satisfaction and decision makingCancer geneticsCommunication about genetic testing with breast and ovarian cancer patients: a scoping reviewGenetics in palliative care: too much to ask?Cancer patients' views and understanding of genome sequencing: a qualitative study
P50
Q27324685-EE42FC5A-0E1E-41B0-A8A5-D8CEC9617963Q34410245-7C4D2B1F-AA82-41E0-9119-057B257F76BFQ34994568-6C215EB3-97DD-4568-8CE4-DD4D880C4A83Q34994574-F72E6103-49E7-4C56-A09A-CE1C3CAC2F68Q35000282-59192450-5748-4E49-A1A8-9C04B1CB5D86Q35870067-DE1446BD-18C0-4BFF-9F25-940C9574A034Q36280191-65E33F1E-C30E-469D-96A7-91070487B0C4Q36393232-A21D2B06-1CE1-4C16-9541-91E90BA2A655Q36720814-E8AF3B98-7E26-4F23-B7A9-06FD64FC03CBQ38881644-399D12E6-78FC-40ED-9A54-815A3363C542Q39209421-8C63A215-CF2C-4113-9436-9B34CFD5E775Q39289151-24C30BDC-7979-48AF-946C-6C77622D1A98Q40732955-821CABD8-B451-4139-8E58-39FCD451BAE0Q43586443-8ADB61BB-5DB2-4511-8984-8D34D94DB8BBQ44809338-C75A967A-0473-4D55-9ABA-48FE3DBC4705Q44833936-55F496B8-03B0-4D2C-842B-4DCC7BC1045CQ47296066-7FD6FB33-F0ED-4655-9AA9-BFF76986CC2CQ48336651-A204229E-EA09-414E-BDB0-77D980E079BDQ50158994-D9CE0B99-291A-4AE7-B46F-D546C643591EQ52603806-2BD06CB2-287D-4001-9289-1559B2D9D5B1Q55243290-04E4DFEE-D145-454C-B007-7DA40DFBE4C1Q67231109-1AF85B98-26F6-48DC-B983-9D003FF6A8F5Q73115515-DC601981-EFCA-45E4-A223-E50D88D50E42Q78412111-F5406801-2C3A-4BA7-85D4-A59B7EBF0C6CQ82664585-A1C1B4EE-733D-46B3-87B2-D74FB8E0E29FQ84578687-8DE46C85-4CE2-4CEB-A909-231742EBDDC2Q90681972-DB42FE68-A79B-4B2E-848D-E8BD6385E2F0Q92215593-9139A655-9A30-4D28-8C35-9480383D86B3Q92931825-BBA183DE-E2DC-4CEA-BDCB-27283EA9B483
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Chris Jacobs
@ast
Chris Jacobs
@en
Chris Jacobs
@es
Chris Jacobs
@nl
Chris Jacobs
@sl
type
label
Chris Jacobs
@ast
Chris Jacobs
@en
Chris Jacobs
@es
Chris Jacobs
@nl
Chris Jacobs
@sl
altLabel
Christine Jacobs
@en
prefLabel
Chris Jacobs
@ast
Chris Jacobs
@en
Chris Jacobs
@es
Chris Jacobs
@nl
Chris Jacobs
@sl
P106
P31
P496
0000-0002-9557-9080